Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy

被引：32

作者：

Jain, Preetesh ^{[1
]}

Nastoupil, Loretta ^{[1
]}

Westin, Jason ^{[1
]}

Lee, Hun Ju ^{[1
]}

Navsaria, Lucy ^{[1
]}

Steiner, Raphael E. ^{[1
]}

Ahmed, Sairah ^{[1
]}

Moghrabi, Omar ^{[1
]}

Oriabure, Onyeka ^{[1
]}

Chen, Wendy ^{[1
]}

Badillo, Maria ^{[1
]}

Flowers, Christopher R. ^{[1
]}

Wang, Michael L. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2021年 / 192卷 / 02期

关键词：

Mantle cell lymphoma (MCL); ibrutinib; brexucabtagene autoleucel; BTK inhibitor; venetoclax; chimeric antigen receptor therapy; non-Hodgkin lymphoma;

D O I：

10.1111/bjh.17197

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E38 / E42

页数：5

共 50 条

[41] Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
Hess, Georg
Dreyling, Martin
Oberic, Lucie
Gine, Eva
Zinzani, Pier Luigi
Linton, Kim
Vilmar, Adam
Jerkeman, Mats
Chen, Jenny M. H.
Ohler, Anke
Stilgenbauer, Stephan
Thieblemont, Catherine
Lambert, Jonathan
Zilioli, Vittorio Ruggero
Sancho, Juan-Manuel
Jimenez-Ubieto, Ana
Fischer, Luca
Eyre, Toby A.
Keeping, Sam
Park, Julie E.
Wu, James J.
Nunes, Ana
Reitan, John
Wade, Sally W.
Salles, Gilles
LEUKEMIA & LYMPHOMA, 2024, 65 (01) : 14 - 25
[42] Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.
Kambhampati, Swetha
Ahmed, Nausheen
Hamadani, Mehdi
Grover, Natalie Sophia
Shadman, Mazyar
Locke, Frederick L.
Gerson, James M.
Frank, Matthew Joshua
Budde, Lihua Elizabeth
Wang, Michael
Hu, Zhen-Huan
Nunes, Ana
Dalton, David
Kloos, Ioana
Lee, Daniel
Xu, Hairong
Pasquini, Marcelo C.
Herrera, Alex Francisco
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/ Refractory Mantle Cell Lymphoma (R/R MCL)
Munoz, Javier
Reagan, Patrick M.
Goy, Andre H.
Miklos, David B.
Zheng, Dan
Fang, Xiang
Shen, Rhine R.
Siddiqi, Rubina
Kloos, Ioana
Kersten, Marie Jose
Wang, Michael
BLOOD, 2022, 140 : 9320 - 9322
[44] Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel ( Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2
Oluwole, Olalekan O.
Reagan, Patrick M.
Miklos, David B.
Locke, Frederick L.
Goy, Andre
Jacobson, Caron A.
Munoz, Javier L.
Forcade, Edouard
Topp, Max S.
Zheng, Dan
Nunes, Ana
Zhang, Wangshu
Shen, Rhine R.
Kloos, Ioana
Kersten, Marie Jose
Wang, Michael L.
BLOOD, 2023, 142
[45] RITUXIMAB MAINTENANCE THERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION PROLONGS PROGRESSION FREE SURVIVAL IN PATIENTS WITH MANTLE CELL LYMPHOMA
Dietrich, S.
Weidle, J.
Meissner, J.
Radujkovic, A.
Ho, A.
Dreger, P.
Witzens-Harig, M.
BONE MARROW TRANSPLANTATION, 2014, 49 : S180 - S181
[46] Rituximab Maintenance Therapy After Autologous Stem Cell Transplantation Prolongs Progression Free Survival In Patients With Mantle Cell Lymphoma
Dietrich, Sascha
Weidle, Julia
Meissner, Julia
Radujkovic, Aleksandar
Ho, Anthony D.
Dreger, Peter
Witzens-Harig, Mathias
BLOOD, 2013, 122 (21)
[47] Real-World Outcomes of Brexucabtagene Autoleucel ( Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics
Kambhampati, Swetha
Ahmed, Nausheen
Hamadani, Mehdi
Kim, Soyoung
Hemmer, Michael T.
Grover, Natalie S.
Shadman, Mazyar
Beitinjaneh, Amer
Budde, L. Elizabeth
Gerson, James
Jacobson, Caron A.
Locke, Frederick L.
Nasta, Dwivedy S.
Wang, Michael L.
Weng, Wen-Kai
Yan, Jiali
Nunes, Ana
Dalton, David
Wu, James J.
Abdeldaim, Amina
Hu, Zhen-Huan
Pasquini, Marcelo
Herrera, Alex F.
BLOOD, 2023, 142
[48] Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma
Dietrich, S.
Weidle, J.
Rieger, M.
Meissner, J.
Radujkovic, A.
Ho, A. D.
Dreger, P.
Witzens-Harig, M.
LEUKEMIA, 2014, 28 (03) : 708 - 709
[49] Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma
S Dietrich
J Weidle
M Rieger
J Meissner
A Radujkovic
A D Ho
P Dreger
M Witzens-Harig
Leukemia, 2014, 28 : 708 - 709
[50] Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Aldoss, Ibrahim
Roloff, Gregory W.
Faramand, Rawan
Kopmar, Noam E.
Lin, Chenyu
Advani, Anjali S.
Dekker, Simone E.
Gupta, Vishal K.
O'Connor, Timothy E.
Jeyakumar, Nikeshan
Muhsen, Ibrahim N.
Valtis, Yannis
Zhang, Amy
Miller, Katharine
Sutherland, Katherine
Dykes, Kaitlyn C.
Ahmed, Mohamed
Chen, Evan
Zambrano, Hector
Bradshaw, Danielle
Mercadal, Santiago
Schwartz, Marc
Tracy, Sean
Dholaria, Bhagirathbhai
Kubiak, Michal
Mukherjee, Akash
Majhail, Navneet
Battiwalla, Minoo
Mountjoy, Luke
Malik, Shahbaz A.
Mathews, John
Shaughnessy, Paul
Logan, Aaron C.
Ladha, Abdullah
Stefan, Maryann
Guzowski, Caitlin
Hoeg, Rasmus T.
Hilal, Talal
Moore, Jozal
Connor, Matthew
O'Dwyer, Kristen M.
Hill, LaQuisa C.
Tsai, Stephanie B.
Sasine, Joshua
Solh, Melhem M.
Lee, Catherine J.
Kota, Vamsi K.
Koura, Divya
Veeraputhiran, Muthu
Blunk, Betsy
BLOOD ADVANCES, 2024, 8 (23) : 6139 - 6147

← 1 2 3 4 5 →